Paper Details

  1. Home
  2. Paper Details

Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.

Author: Abril-FornagueraJordi, BalaseviciuteUgne, FriedmanScott L, GehDaniel, HaberPhilipp K, LeslieJack, LlovetJosep M, MaedaMiho, MannDerek A, MesropianAgavni, MontironiCarla, PeixJudit, Piqué-GiliMarta, PuigvehíMarc, Ramon-GilErik, SaberiBehnam, SiaDaniela, TorrensLaura, Torres-MartínMiguel, WilloughbyCatherine E

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study explores the molecular and immunomodulatory effects of lenvatinib alone or in combination with the anti-PD1 immune checkpoint inhibitor, pembrolizumab, in patients with advanced hepatocellular carcinoma.
Paper Details　
Original Abstract of the Article :
Lenvatinib is an effective drug in advanced HCC. Its combination with the anti-PD1 (programmed cell death protein 1) immune checkpoint inhibitor, pembrolizumab, has generated encouraging results in phase Ib and is currently being tested in phase III trials. Here, we aimed to explore the molecular an...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/hep.32023

データ提供：米国国立医学図書館（NLM）

Immunomodulatory Effects of Lenvatinib Plus Anti-PD1 in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC), a type of liver cancer, is a significant health concern worldwide. This research investigates the immunomodulatory effects of lenvatinib, a drug used to treat advanced HCC, when combined with anti-PD1 (programmed cell death protein 1), an immune checkpoint inhibitor. The study aims to explore the potential synergistic effects of this combination therapy on the immune system and its implications for HCC treatment.

Exploring the Immunomodulatory Potential of Lenvatinib Plus Anti-PD1

The study explores the potential of lenvatinib, a drug already used for advanced HCC, in combination with anti-PD1, an immune checkpoint inhibitor. This research aims to understand how this combination affects the immune system in patients with HCC. The study also explores the possibility of identifying specific patient groups who might benefit most from this combination therapy.

Potential for Improved HCC Treatment

This research highlights the potential of combination therapy involving lenvatinib and anti-PD1 in treating HCC. It explores the potential for this combination to enhance the immune system's ability to fight cancer. This study suggests that further investigation of this combination therapy could lead to improved treatment strategies for HCC. It's important to continue research in this area to explore the potential of these therapies and their implications for patient care.

Dr.Camel's Conclusion

This research explores the potential of a new approach to treating HCC, combining lenvatinib with anti-PD1. It's like using a combination of strategies to navigate a complex desert—one strategy might help overcome a particular obstacle, while another might provide a different advantage. This research suggests that this combination therapy could enhance the immune system's ability to fight HCC, potentially leading to improved treatment outcomes. It highlights the need for ongoing research to further understand the synergistic effects of this combination therapy.

Date :
  1. Date Completed 2022-01-13
  2. Date Revised 2022-04-24
Further Info :

Pubmed ID

34157147

DOI: Digital Object Identifier

10.1002/hep.32023

Related Literature

Article Analysis
・Effects of lenvatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.